Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Alexion Pharmaceuticals"
Count: 201
Selected: 0
NCT02329327A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
NCT05109390A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
NCT03124368A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
NCT03472885Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
NCT05047484A Study of Multiple Doses of ALXN2050 in Healthy Adults
NCT05047458A Study of Single-dose ALXN2050 in Healthy Adults
NCT05016206A Study of the Cardiac Effects of Danicopan in Healthy Adults
NCT03555539Study of Danicopan in Participants With Hepatic Impairment
NCT03384186A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
NCT04940559Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants
NCT03108274A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants
NCT04935294Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
NCT03053102Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04999020Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
NCT04469465Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
NCT04889690Study of Multiple Doses of Danicopan in Healthy Participants
NCT04889677Study of a Single Dose of Danicopan in Healthy Participants
NCT04889391Study of Radiolabeled Danicopan in Healthy Male Participants
NCT04660890A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
NCT04933682Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
NCT04551586A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants
NCT04564339Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT01374360Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
NCT05047523Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
NCT04952545Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
NCT04743804Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
NCT04956276Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
NCT04248465An Efficacy and Safety Study of Ravulizumab in ALS Participants
NCT02946463ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03181633A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04982289Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
NCT04730804A Study of ALXN1830 in Healthy Adult Participants
NCT04631562Study of ALXN1820 in Healthy Adult Participants
NCT04526197Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
NCT03661528Trial of Andexanet Alfa in ICH Patients Receiving an Oral FXa Inhibitor
NCT03369236A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
NCT03759366A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
NCT05097989Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)
NCT03459443A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
NCT04233073Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
NCT00040144Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
NCT00034359Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
NCT04802083COVID-19 Soliris Expanded Access Protocol
NCT02273596Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
NCT04320602Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
NCT04958135Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants
NCT04980248Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
NCT04369469Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
NCT03920293Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
NCT05019521A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration